Rising number of alliances to drive generics cancer drugs market, says RNCOS

7 September 2011

Increasing collaborations pertaining to cancer generics drugs have intensified in the recent times, says market research group RNCOS in its latest research study. The report, titled Cancer Generics Market Analysis, reveals that pharmaceutical companies around the world are now resorting to the generic versions of top branded cancer drugs to support the demand without the price issues.

Earlier, these companies were not so inclined towards generic oncology drugs due to low profitability. But the rising concerns over health care expenditure in the developed nations have forced the governments to support the uptake of generic versions.

The study indicates that companies including Actavis, Endo Pharmaceuticals Holdings, Nichi-Iko Pharmaceutical, Natco Pharma, Akrihin and AstraZeneca have recently forayed investments to widen their generics cancer drug pipeline.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >